Skip to main content

Table 2 Laboratory results of the studied groups

From: Role of engulfment and cell motility 1 (ELMO1) gene polymorphism in development of diabetic kidney disease

Variables Group1
(n=100)
Group2
(n=102)
Group 3
(n=102)
P value of Kruskal-Wallis test Post hoc test
FBS (mg/dl) P1 0.062
 Mean ±SD 169.72 ± 34.19 158.62 ± 33.76 85.45 ± 7.38 <0.001 P2 <0.001
 Median (IQR) 177(138–188) 156.5 (128–180) 87 (80–90)   P3 <0.001
2-hPPG (mg/dl) P1 0.249
 Mean ±SD 273.38 ± 52.26 262.16 ± 40.43 125.49 ± 12.32 <0.001 P2 <0.001
 Median (IQR) 266 (228–311) 258 (245–288) 123(120–129)   P3 <0.001
HbA1c % P1 <0.001
 Mean ±SD 8.30 ± 0.83 7.44 ± 0.85 4.83 ± 0.25 <0.001 P2 <0.001
 Median (IQR) 8.2 (7.6–8.8) 7.3 (6.9–7.9) 4.8 (4.6–5.0)   P3 <0.001
Creatinine (mg/dl) P1 <0.001
 Mean ±SD 1.41 ± 0.23 1.00 ± 0.11 0.86 ± 0.11 <0.001 P2 <0.001
 Median (IQR) 1.4(1.3–1.5) 1.0(0.9–1.1) 0.90 (0.80–1.0)   P3 <0.001
eGFR (mL/min/1.73 m2) P1 <0.001
 Mean ±SD 54.81 ± 12.80 84.37 ± 10.80 99.52 ± 10.41 <0.001† P2 <0.001
 Median (IQR) 54.65(46.55–62.84) 81.78 (76.68–89.86) 97.76 (93.16–106.46)   P3 <0.001
Total cholesterol (mg/dl)      P1 0.552
 Mean ±SD
 Median (IQR)
247.40 ± 23.78
250(225–269)
243.72 ± 19.80
239(231–262)
162.13 ± 14.89
161(154–176)
<0.001 P2 <0.001
P3 <0.001
Triglyceride (mg/dl) P1 0.994
 Mean ±SD 181.08 ± 20.86 181.86 ± 28.22 127.84 ± 11.20 <0.001 P2 <0.001
Median (IQR) 183 (168–196) 185 (174–198) 128(122–135)   P3 <0.001
HDL-C (mg/dl) P1 0.145
 Mean ±SD 35.22 ± 4.77 36.37 ± 3.42 49.41 ± 5.45   P2 <0.001
 Median (IQR) 35(32–39) 38 (34–39) 49(45–54) <0.001 P3 <0.001
LDL-C (mg/dl)      P1 0.044
 Mean ±SD 177.94 ± 22.12 170.25 ± 18.47 86.49 ± 10.60 <0.001 P2 <0.001
 Median (IQR) 182(155–195.8) 168 (155–168) 87 (79–98)   P3 <0.001
AIP P1 0.008
 Mean ±SD 0.37 ± 0.09 0.34 ± 0.05 0.05 ± 0.06 <0.001 P2 <0.001
 Median (IQR) 0.36 (0.32–0.42) 0.34 (0.31–0.38) 0.05 (0.0–0.10)   P3 <0.001
ACR (mg/g creatinine) P1 <0.001
 Mean ±SD 132.14 ± 82.21 18.09 ± 5.72 15.21 ± 5.65 <0.001 P2 <0.001
 Median (IQR) 98 (85–150) 18 (14–22) 15 (11–19)   P3 0.001
  1. Group 1 DKD patients, Group 2 diabetic patients without DKD, Group 3 healthy controls, FBS fasting blood sugar, 2-hPPG 2-hour post prandial blood sugar, HbA1c hemoglobin A1C, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, AIP atherogenic index of plasma, ACR albumin/creatinine ratio, P1 group 1 vs group 2, P2 group 1 vs group 3, P3 group 2 vs group 3, for ANOVA test, IQ interquartile range. Statistically significant at p ≤ 0.05